Pharma BD Deal Intelligence
Daiichi Sankyo paid ~$410M for Ambit Biosciences to acquire quizartinib, a selective FLT3 inhibitor for AML. Vanflyta received FDA approval in 2023 as the first FLT3 inhibitor approved specifically for newly diagnosed FLT3-ITD+ AML—addressing one of the highest-risk leukemia subtypes.
Daiichi Sankyo to acquire Ambit Biosciences for $15 per share plus CVR worth up to $4.50 for total deal value of approximately $410 million
EHA survival data sets Daiichi Sankyo quizartinib back on track after earlier setbacks in FLT3-positive acute myeloid leukemia trials
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Daiichi Sankyo acquired Ambit Biosciences for ~$410M for cancer compound quizartinib.
Quizartinib (Vanflyta, Daiichi Sankyo) is the lead FLT3-ITD selective TKI; MOA-stratified FLT3-mutated AML landscape. FLT3 inhibitors - Type II selective FLT3-ITD (same class as quizartinib): Vanflyta (quizartinib, Daiichi Sankyo) received FDA approval July 2023 for newly diagnosed FLT3-ITD+ AML with intensive induction/consolidation and maintenance based on QuANTUM-First; Daiichi reported FY2024 Vanflyta sales ~JPY 26B (~$170M) ramping. FLT3 inhibitors - Type I multikinase (competing class, activity against ITD and TKD): Xospata (gilteritinib, Astellas) is approved relapsed/refractory FLT3+ AML monotherapy (ADMIRAL) with 2024 sales ~JPY 130B ($850M) per Astellas reporting; Rydapt (midostaurin, Novartis) is approved newly diagnosed FLT3+ AML with chemotherapy (RATIFY), generating ~$500M 2023 sales. Earlier-generation TKIs: sorafenib (Nexavar) used off-label maintenance post-allo-HSCT; crenolanib (Arog, Phase 3 ongoing). Chemotherapy backbone and non-FLT3 agents: Vidaza (azacitidine) + Venclexta (venetoclax, AbbVie/Genentech, $3.4B 2024 Venclexta hematology sales) for unfit/elderly; Mylotarg (gemtuzumab ozogamicin) CD33 ADC; Vyxeos liposomal cytarabine/daunorubicin for secondary AML. Commercial threat sizing for quizartinib: 1L competition with midostaurin is the primary battle; quizartinib's QuANTUM-First OS benefit and maintenance positioning provide differentiation, but gilteritinib dominates R/R and is encroaching on earlier-line use via combination trials.
AC410 is a JAK2-selective small-molecule inhibitor; the JAK-inhibitor class in myeloproliferative neoplasms (MPN) and JAK2-driven diseases is crowded and segmented by selectivity. JAK1/JAK2 inhibitors (direct competitor class): Jakafi (ruxolitinib, Incyte/Novartis) is the category anchor, approved for myelofibrosis, polycythemia vera, and steroid-refractory acute and chronic GVHD; Incyte reported 2024 Jakafi net product revenue of ~$2.77B per 10-K. JAK2/FLT3 inhibitors: Inrebic (fedratinib, BMS, acquired from Celgene) approved 2019 intermediate/high-risk myelofibrosis. JAK2/IRAK1 inhibitors: Vonjo (pacritinib, Sobi/CTI BioPharma) FDA-approved February 2022 for myelofibrosis with thrombocytopenia (platelets <50,000). JAK1/JAK2/ACVR1 inhibitors: Ojjaara/Omjjara (momelotinib, GSK) FDA-approved September 2023 for myelofibrosis with anemia, differentiating on hemoglobin improvement; GSK reported 2024 Ojjaara sales ~GBP 100M+ growing. Pan-JAK (inflammatory, adjacent but competing for JAK2-related inflammation): Xeljanz (tofacitinib, Pfizer) in rheumatology. Emerging selective JAK2 V617F-specific inhibitors: Ajax Therapeutics' AJ1-11095 (Phase 1). Commercial threat sizing for AC410: ruxolitinib dominates 1L myelofibrosis with ~80% share; fedratinib, pacritinib, and momelotinib carve thrombocytopenia/anemia sub-segments. AC410 development discontinued post-Daiichi/Ambit integration; selective JAK2 V617F inhibition is the remaining white space, now occupied by Ajax and Cellenkos programs.
CEP-32496 (agerafenib/RXDX-105) is a pan-RAF + RET inhibitor; the BRAF-mutated cancer landscape is tumor-agnostic and MOA-segmented. BRAF V600E/K selective inhibitors (direct class): Zelboraf (vemurafenib, Roche, first approved 2011 melanoma), Tafinlar (dabrafenib, Novartis) + Mekinist (trametinib) combo dominates BRAF V600E melanoma adjuvant and metastatic plus NSCLC, anaplastic thyroid, tumor-agnostic pediatric/adult (Novartis reported 2024 Tafinlar+Mekinist combined sales ~$1.9B), Braftovi (encorafenib, Pfizer) + Mektovi (binimetinib) in melanoma, NSCLC, and + Erbitux (cetuximab) in BRAF V600E CRC. Next-generation RAF inhibitors (same class as CEP-32496): Day One/Ojemda (tovorafenib, FDA-approved April 2024 for pediatric low-grade glioma with BRAF fusion/V600, tumor-agnostic pan-RAF), Springworks/Plexxikon's exarafenib, Kinnate Biopharma's exarafenib/KIN-2787 (Phase 1 in RAF/RAS-driven tumors, company wound down 2024), Erasca's ERAS-254. MEK inhibitors (downstream combinations): trametinib, binimetinib, cobimetinib (Cotellic, Roche). Commercial threat sizing for CEP-32496: the BRAF V600 segment is saturated by dabrafenib/trametinib and encorafenib-based combinations; tovorafenib (Ojemda) carved the pediatric/BRAF-fusion niche in 2024. Non-V600 BRAF class II/III tumors are the only open wedge, but CEP-32496 development was effectively deprioritized post-Ignyta/Roche acquisition.
AC708 is a selective CSF1R small-molecule inhibitor; CSF1R-driven diseases (principally tenosynovial giant cell tumor/TGCT, pigmented villonodular synovitis, and exploratory macrophage-driven autoimmune and neurodegenerative indications) have a compact landscape. CSF1R small-molecule inhibitors (direct class): Turalio (pexidartinib, Daiichi Sankyo) received FDA approval August 2019 for symptomatic TGCT with REMS restrictions due to hepatotoxicity; Romvimza (vimseltinib, Deciphera/Ono) received FDA approval February 2025 for TGCT based on MOTION trial positive Phase 3, positioning as cleaner safety alternative to pexidartinib; Ojjaara/Omjjara (momelotinib, GSK) has CSF1R activity but is positioned as JAK1/2 inhibitor. Anti-CSF1R monoclonal antibodies: Syndax's axatilimab (Niktimvo, BLA approval August 2024) for chronic graft-versus-host disease third-line post-JAK/BTK failure, representing the first approved CSF1R mAb; Roche's emactuzumab (Phase 2 discontinued in TGCT). Early-pipeline CSF1R TKIs: Plexxikon's PLX73086, AC708 itself (Ambit/Daiichi, deprioritized), and cabiralizumab (FivePrime/BMS, discontinued in pancreatic cancer). Commercial threat sizing for AC708: TGCT market is now split between Turalio (2024 Daiichi sales ~JPY 13B) and newly approved Romvimza; AC708's selective profile never advanced beyond Phase 1, and the commercial window was closed by vimseltinib's cleaner safety profile.
Daiichi Sankyo acquired Ambit Biosciences for ~$410M for cancer compound quizartinib.
Transaction valued at $410M. Daiichi Sankyo acquired Ambit Biosciences for ~$410M for cancer compound quizartinib.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Daiichi Sankyo Company, Limited / Ambit Biosciences (this deal) | 2006 | $410M | 62 |
| Daiichi Sankyo Company, Limited / Zepharma Inc. | 2006 | $200M | 57 |
| Daiichi Sankyo Company, Limited / Plexxikon Inc. | 2011 | $935M | 51 |
| Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited | 2008 | $4.6B | 14 |
| Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc. | 2025 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
← Browse all deals · How we score deals
More: 2006 deals · Daiichi Sankyo Company, Limited deals · Oncology deals